Balicatib
CAS No. 354813-19-7
Balicatib ( AAE581 )
产品货号. M14213 CAS No. 354813-19-7
Balicatib 是组织蛋白酶 K 的抑制剂,IC50 值为 1.4nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥633 | 有现货 |
|
| 10MG | ¥1036 | 有现货 |
|
| 25MG | ¥1851 | 有现货 |
|
| 50MG | ¥2911 | 有现货 |
|
| 100MG | ¥4041 | 有现货 |
|
| 200MG | ¥5661 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥710 | 有现货 |
|
生物学信息
-
产品名称Balicatib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Balicatib 是组织蛋白酶 K 的抑制剂,IC50 值为 1.4nM。
-
产品描述Balicatib is an inhibitor of cathepsin K with IC50 value of 1.4nM.Balicatib is highly selective against cathepsin K over cathepsin B, L and S in the in vitro enzyme assay. However, the selectivity is not so high in cell-based enzyme assay. The lysosomotropic character of balicatib results in its accumulation in lysosomes and the subsequent nonselective off-target effects. The off-target effects also cause the skin adverse events of balicatib. As a cathepsin K inhibitor, balicatib is developed for osteoporosis. It has been reported to reduce the biochemical markers of bone resorption and increase bone mineral density in ovariectomized monkeys.(In Vitro):Balicatib (0-10 μM) shows less than 1.5-fold accumulation of Type I collagen at concentrations up to 10 μM in human dermal fibroblasts.(In Vivo):Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) partially prevented ovariectomyinduced changes in bone mass, inhibited bone turnover at most sites, and had an stimulatory effect on periosteal bone formation in cynomolgus monkeys.
-
体外实验Balicatib (0-10 μM) shows less than 1.5-fold accumulation of Type I collagen at concentrations up to 10 μM in human dermal fibroblasts.
-
体内实验Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) partially prevented ovariectomyinduced changes in bone mass, inhibited bone turnover at most sites, and had an stimulatory effect on periosteal bone formation in cynomolgus monkeys. Animal Model:11-13 years, female cynomolgus monkeys (Macaca fascicularis)Dosage:0, 3, 10, 50 mg/kg Administration:Oral gavage; twice daily for 18 months Result:Completely prevented ovariectomy-induced increases in BFR/BS in cancellous bone of vertebra and femur and in osteonal and endocortical bone of vertebra, significantly decreased bone formation rates.
-
同义词AAE581
-
通路Proteasome/Ubiquitin
-
靶点Cysteine Protease
-
受体Cathepsin K
-
研究领域Metabolic Disease
-
适应症——
化学信息
-
CAS Number354813-19-7
-
分子量411.54
-
分子式C23H33N5O2
-
纯度>98% (HPLC)
-
溶解度Soluble in DMSO
-
SMILESO=C(NC1(C(NCC#N)=O)CCCCC1)C2=CC=C(N3CCN(CCC)CC3)C=C2
-
化学全称N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(4-propylpiperazin-1-yl)benzamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Jerome C, et al. Osteoporos Int. 2012 Jan;23(1):339-49.
产品手册
关联产品
-
(1S,2R)-Alicapistat
(1S,2R)-Alicapistat ((1S,2R)-ABT-957) 是一种具有口服活性的人钙激活中性蛋白酶 (calpains 1 和 2) 的选择性抑制剂,可能用于阿尔茨海默病 (AD) 的研究。 Alicapistat 可减轻羰基还原的代谢倾向,对 calpain 1 的 IC50 为 395 nM。
-
Calpain Inhibitor XI...
(Rac)-Calpain Inhibitor XII 是可逆的,选择性的钙蛋白酶 I (calpain I; μ-calpain) 抑制剂,Ki 值为 19 nM。(Rac)-Calpain Inhibitor XII 对钙蛋白酶 II (calpain II; m-calpain; Ki=120 nM) 和组织蛋白酶 B (cathepsin B; Ki=750 nM) 具有较低的亲和力。(Rac)-Calpain Inhibitor XII 有潜力用于研究钙蛋白酶在多种过程中的作用,包括嗜中性粒细胞趋化性,神经元信号传导和心脏对损伤的反应。
-
Aurantiamide acetate
首次从青霉曲霉的发酵液中分离得到醋酸橙酰胺。 Aurantiamideacetate 是一种选择性的、口服活性的组织蛋白酶抑制剂。 Aurantiamideacetate 具有抗炎活性,可用于炎症性疾病的研究。
021-51111890
购物车()
sales@molnova.cn

